

Attorney Docket No.: 6569.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Serial No.: 10/693,161

Group Art Unit: To be assigned

Filed: October 24, 2003

Examiner: To be assigned

For: Novel Compounds, Their Preparation and Use

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (17)


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **January 5, 2004**

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)



Attorney Docket No.: 6569.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Application No.: 10/693,161

Group Art Unit: To be assigned

Filed: October 24, 2003

Examiner: To be assigned

For: Novel Compounds, Their Preparation and Use

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 97/27847 A1
2. WO 97/27857 A1
3. WO 97/28115 A1
4. WO 97/28137 A1


5. WO 97/28149 A1
6. WO 97/48674 A1
7. WO 98/27974 A1
8. WO 99/04815 A1 (along with translation of Disclosure of Invention Claims)
9. WO 01/00603 A1
10. WO 01/25181 A1 (along with translation of Disclosure of Invention and Claims)
11. WO 01/79197 A1
12. WO 02/059098 A1
13. WO 02/14291 A1
14. Berger et al., Journal of Biological Chemistry, Vol. 274, No. 10, pages 6718-6725 (1999)
15. Leibowitz et al., FEBS Letters, Vol 473, pages 333-336 (2000)
16. Oliver et al., Proceedings of the National Academy of Sciences of the USA, Vol. 98, pages 5306-5311 (2001)
17. Muoio et al., Journal of Biological Chemistry, Vol. 277, No. 29, pages 26089-26097 (2002)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: January 5, 2004

Respectfully submitted,


Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6569.200-US

Serial No. 10/693,161

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant Jeppesen et al.

(Use several sheets if necessary)

Filing Date October 24, 2003

Group To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/27847 A1	8/7/97	PCT				
	WO 97/27857 A1	8/7/97	PCT				
	WO 97/28115 A1	8/7/97	PCT				
	WO 97/28137 A1	8/7/97	PCT				
	WO 97/28149 A1	8/7/97	PCT				
	WO 97/48674 A1	12/24/97	PCT				
	WO 98/27974 A1	7/2/98	PCT				
	WO 99/04815 A1	2/4/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Berger et al., Journal of Biological Chemistry, Vol. 274, No. 10, pages 6718-6725 (1999)
		Leibowitz et al., FEBS Letters, Vol 473, pages 333-336 (2000)
		Oliver et al., Proceedings of the National Academy of Sciences of the USA, Vol. 98, 5306-5311 (2001)
		Muoio et al., Journal of Biological Chemistry, Vol. 277, No. 29, pages 26089-26097 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and

Sheet 2 of 2

Serial No. 10/692,561

Group To be assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

[illegible][illegible]

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.